Skip to content
Hair Pipeline
← Remedies and supplements

Do cystine supplements like Pantogar and Priorin help hair loss?

The cystine products tested for hair loss combine L-cystine with other ingredients, usually B vitamins, and the trials behind them are small. The early placebo-controlled ones, from 1990 to 2000, mostly reported what share of hairs were in their growing phase, which is not the same as having more hair, and most later studies were run or paid for by the companies selling the products, usually without a placebo. In France, Cystine B6 Bailleul and Gélucystine are licensed medicines, but for fragile nails or hair, not hair loss, and the public medicines database records no assessment of their clinical benefit by the national health authority (HAS). At its labelled dose, four tablets a day for one month, Cystine B6 Bailleul provides about 165 mg of vitamin B6 a day; the European upper limit for long-term daily intake is 12 mg, and the product information says it must not be used for long periods.

Pantogar and other early trials

Pantogar, made by Merz and also called Pantovigar, combines medicinal yeast, thiamine, calcium pantothenate, keratin and para-aminobenzoic acid with cystine, 20 mg in the formula the European guideline describes. A 1990 double-blind study of 60 people with diffuse shedding reported Pantogar effective and placebo ineffective on hair swelling and trichograms; the abstract gives no figures. A 1993 double-blind trial in 72 women found an unnamed product of B vitamins and L-cystine better than placebo on similar measures. The European guideline's evidence table summarises a 1998 trial of 60 people in five groups: over 50 weeks, hand-counted hairs rose 29% from baseline on a supplement of L-cystine, L-methionine, copper and zinc, against 11% on a placebo supplement. None of these sources says who paid. Merz registered an open trial adding Pantovigar to minoxidil in 74 women after its main results had been collected, and a single-group study of a vegan version after it had ended; it has posted results for neither on the registry.

Priorin and millet extract

Priorin capsules, from Bayer, contain millet extract, pantothenic acid, biotin and 3 mg of L-cystine each; the 2026 study below describes the product as a food supplement. A 2000 study compared a combination of millet extract, cystine and calcium pantothenate with placebo for six months in 40 women with pattern hair loss; the European guideline's evidence table records a mean change in anagen rate of 12.1 on the supplement against 8.4 on placebo (p = 0.0225). A 2026 study paid for by Bayer, which also took part in its design and writing, followed 112 healthy people with light seasonal shedding, about half of them in France, for 12 weeks with no comparison group. Hairs lost in a shampoo test fell from 47 to 19, and the authors write that "a contribution of natural seasonal variation cannot be excluded". Investigators judged 97 of the 139 adverse events related to the product; headache was the most frequent.

What an anagen rate measures

A scalp hair goes through a cycle of three to five years: it grows in a phase called anagen, then rests in a phase called telogen and falls out. Normally 85 to 90% of scalp hairs are growing. A trichogram examines plucked hairs under a microscope and counts how many are in each phase; a phototrichogram photographs a small shaved patch of scalp. The anagen rate is the percentage of those hairs that are growing. A falling rate can lead to thinning, so a rise is a good sign, but it is a share of the hairs examined, not a count of the hair on your head, and in the 2000 study the placebo group's rate rose too. Hair swelling, measured in the 1990 and 1993 trials, is a test of hair quality, not of hair loss.

Newer blends

In newer blends the cystine cannot be credited with any result. A 2025 placebo-controlled trial of ISDIN's Lambdapil capsules, which also contain saw palmetto, pumpkin seed, Pygeum, zinc and biotin, enrolled 80 adults with chronic shedding or pattern hair loss; the supplement group gained 12.3 hairs per square centimetre over six months, significantly more than placebo. ISDIN paid for the study and six of its ten authors work there. A 2025 Italian trial added a capsule of saw palmetto, pumpkin seed, L-cystine, vitamin C and zinc to treatments that were mostly minoxidil or finasteride, with no placebo, and its two named authors are employees of the company selling it. A 2023 study of Bailleul's Cystiphane tablets, with arginine, cystine, zinc and vitamin B6, by University of Bologna dermatologists, evaluated 18 of 20 people with telogen effluvium and had no comparison group.

Medicines in France, with no assessed benefit

In France, three medicines based on L-cystine are licensed for nails or hair and sold without prescription: Cystine B6 Bailleul and its Biogaran copy, with 500 mg of L-cystine and 50 mg of pyridoxine hydrochloride (vitamin B6) per tablet, and Gélucystine, with 500 mg of L-cystine. Their indication is a supportive treatment for fragile nails or hair, and for Cystine B6 Bailleul also corneal healing, not hair loss. Bépanthène 100 mg tablets, which contain dexpanthenol, a form of vitamin B5, and no cystine, are licensed as a supportive treatment for diffuse hair loss. All four are freely priced and not reimbursed, and the public medicines database records no assessment of their clinical benefit by the transparency committee of the HAS. Pantogar is not in that database. Cystiphane and Forcapil products containing L-cystine, and a product named Pantogar, are declared as food supplements in the French agriculture ministry's public register, and the EU's authorised health claims include none for cystine and hair.

What guidelines and reviews say

The 2017 European guideline on pattern hair loss makes no recommendation either way. For the millet-seed combination and the other products in its miscellaneous chapter, it says: "We cannot make a recommendation for or against a treatment with the mentioned molecules, substances and interventions at the present time." It summarises a study of 61 women on 2% minoxidil, with or without Pantovigar, as showing a comparable fall in resting hairs after nine months. A 2023 systematic review in JAMA Dermatology was more positive: it listed Pantogar and Lambdapil among the supplements whose highest-quality studies showed a potential benefit, and said its findings should be read in the context of each study's design.

Vitamin B6 in Cystine B6

The labelled dose of Cystine B6 Bailleul and its Biogaran copy, four tablets a day for one month, provides 200 mg a day of pyridoxine hydrochloride, which is about 165 mg of vitamin B6. The European Food Safety Authority's upper limit for adults is 12 mg of vitamin B6 a day from all sources, taken over the long term; it was set to prevent peripheral neuropathy, nerve damage that the authority says appears sooner at higher doses. The product information says the medicine must not be used for long periods, warns about taking several products that contain vitamin B6, and lists peripheral neuropathy after high doses or prolonged use. Cystine B6 Bailleul and Gélucystine must not be taken by people with cystinuria.

Related questions

Sources

  1. The efficacy of drug therapy in structural lesions of the hair and in diffuse effluvium--comparative double blind study · Schweizerische Rundschau für Medizin Praxis, 1990 · PMID 1709511
  2. Systemic therapy of diffuse effluvium and hair structure damage · Der Hautarzt, 1993 · PMID 7687592
  3. "Let Food be Thy Medicine": Value of Nutritional Treatment for Hair Loss · International Journal of Trichology, 2021 · PMID 34934293
  4. A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (NCT01900041) · ClinicalTrials.gov, 2013
  5. Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss (NCT05943860) · ClinicalTrials.gov, 2023
  6. S3 - European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men · European Dermatology Forum, 2017
  7. Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review · JAMA Dermatology, 2023 · PMID 36449274
  8. Effectiveness, Tolerability, and Acceptance of a Food Supplement in the Management of Non-Illness-Related Hair Loss and Thinning · Journal of Cosmetic Dermatology, 2026 · PMID 42144810
  9. Targeted Nutritional Supplementation for Telogen Effluvium: Multicenter Study on Efficacy of a Hydrolyzed Collagen, Vitamin-, and Mineral-Based Induction and Maintenance Treatment · International Journal of Trichology, 2022 · PMID 35531488
  10. Oral Supplementation with l-Cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A Double-Blind, Placebo-Controlled, Randomized Clinical Study · Skin Appendage Disorders, 2025 · PMID 39911983
  11. Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial on 225 Subjects · Journal of Cosmetic Dermatology, 2025 · PMID 40853071
  12. Clinical study on the efficacy and tolerability of an oral supplement based on arginine, l-cystine, zinc and B6 vitamin (Cystiphane®) in patients with telogen effluvium · Italian Journal of Dermatology and Venereology, 2023 · PMID 37278502
  13. CYSTINE B6 BAILLEUL, comprimé pelliculé · Base de données publique des médicaments, 2026
  14. CYSTINE / VITAMINE B6 BIOGARAN CONSEIL 500 mg/50 mg, comprimé pelliculé · Base de données publique des médicaments, 2026
  15. GELUCYSTINE 500 mg, gélule · Base de données publique des médicaments, 2026
  16. BEPANTHENE 100 mg, comprimé · Base de données publique des médicaments, 2026
  17. Base de Données Publique des Médicaments · Ministère du Travail, de la Santé, des Solidarités et des Familles; ANSM, 2026
  18. Déclarations de compléments alimentaires · Ministère de l'Agriculture, de l'agro-alimentaire et de la souveraineté alimentaire, 2026
  19. Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health · European Commission, 2012
  20. Scientific opinion on the tolerable upper intake level for vitamin B6 · EFSA Journal, 2023 · PMID 37207271

Checked against its sources on 2026-10-29, by us, not by a doctor. A research register, not medical advice: talk to a dermatologist about your own case. See why we're not doctors.